Axis Shield says granted Chinese patent for its Afinion diagnostic technology: related news

Axis-Shield says granted Chinese patent for its Afinion diagnostic technology

LONDON (Thomson Financial) - Axis-Shield Plc, the diagnostics company, announced Monday that it has received notice of approval of its patent application covering its Afinion technology in China.

DP6946 Patent Thickets and the Market for Innovation: Evidence from Settlement of Patent Disputes

We study how fragmentation of patent rights (‘patent thickets’) and the formation of the Court of Appeal for the Federal Circuit (CAFC) affected the duration of patent disputes, and thus the speed of technology diffusion through licensing. We develop a model of patent litigation which predicts faster settlement agreements when patent rights are fragmented and when there is less uncertainty about court outcomes, as was associated with the ‘pro-patent shift’ of CAFC. The model also predicts that the impact of fragmentation on settlement duration should be smaller under CAFC. We confirm these predictions empirically using a dataset that covers nearly all patent suits in U.S. federal district courts during the period 1975-2000. Finally, we analyze how fragmentation affects total settlement delay, taking into account both reduction in duration

Axis-Shield granted new patent

Axis-Shield has received notice of approval of its US patent application governing the measuring methodology for HbA1c within the Afinion cassette for detection of this important marker of diabetic patient compliance.

Alnylam Loses Challenge In Europe On Key Patent Covering Gene-Silencing Technology

July 14, 2008 (FinancialWire) Shares of Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) fell after the company said that it lost a challenge in Europe on a key patent which covered certain areas of its gene-silencing technology. Alnylam said claims on the "Glover" patent were overturned by the Opposition Division of the European Patent Office. The patent is licensed from Cancer Research Technology Ltd. and Alnylam said it plans to appeal the decision. Alnylam said that the decision does not alter the position of the company's intellectual property for developing and commercializing RNAi therapeutics, nor does it impact any ongoing business development discussions. The patent is one of 11 held by Alnylam. The goal of gene-silencing, or RNA-based, treatments is to turn off, or silence- the gene at the root of a medical condition, treating the a

Patent Granted in Mexico for Breakthrough CodecSys Video Compression Technology from Broadcast International

today announced that a patent for its breakthrough multi-codec video compression technology, CodecSys, has been granted by the Mexico patent office. The technology slashes bandwidth requirements for video transmitted over satellite, cable, IP, and wireless media. CodecSys allows, for example, up to twelve HDTV channels to be broadcast over the same media which currently support only two.

Patent Granted in Mexico for Breakthrough CodecSys Video Compression Technology from Broadcast International

SALT LAKE CITY - Broadcast International (OTCBB: BCST) (“BI�) today announced that a patent for its breakthrough multi-codec video compression technology, CodecSys, has been granted by the Mexico patent office. The technology sl

Geometric Granted Patent for Shape-Based Search Technology

Mumbai, India, August 20, 2008: Geometric Limited (BSE: 532312, NSE: GEOMETRIC), a leader in Product Lifecycle Management (PLM) solutions and technologies, was granted a patent titled “Geometry based search method for 3D CAx/PDM repositories” by the US Patent and Trademark Office (Patent no. 7,397,473). The patent outlines algorithms and methods to locate 3D CAD models based on shape data, unlike text and attribute based search methods.

JPEG Patent's Single Claim Rejected (And Smacked Down For Good Measure)

We've been covering the ongoing saga of an old patent we've referred to as the "JPEG Patent." This actually isn't the first patent we've called the JPEG Patent, because multiple people claimed to hold patents over the technology that goes into a JPEG image. But, this one was rather special. The patent had been used, repeatedly, by lawyer Ray Niro, against a wide range of opponents, including a patent system critic. The end result was a drawn out review process where all of the original claims were rejected, but a single new claim was added to the patent, which Niro insisted covered JPEGs on a website.

Day4 Energy Gains Chinese Patent Approval for Proprietary Solar Technology

BURNABY, BC, Aug. 21 /CNW/ - Day4 Energy Inc. (TSX: DFE - News), a leading manufacturer of high performance, cost-effective solar electric modules, today announced that the China Patent & Trademark office has issued a decision to award the company a patent for its core Day4 Electrode(TM) solar technology. The Chinese patent approval adds to existing intellectual property protection the company holds in key global markets including the European Union, United States, India and Mexico.

Day4 Energy Gains Chinese Patent Approval for Proprietary Solar Technology

Vancouver, BC, August 21, 2008--(T-Net)--Day4 Energy Inc. (TSX: DFE), a leading manufacturer of high performance, cost-effective solar electric modules, today announced that the China Patent & Trademark office has issued a decision to award the company a patent for its core Day4 Electrode solar technology. The Chinese patent approval adds to existing intellectual property protection the company holds in key global markets including the European Union, United States, India and Mexico.

Day4 Energy Gains Chinese Patent Approval for Proprietary Solar Technology

Vancouver, BC, August 21, 2008--(T-Net)--Day4 Energy Inc. (TSX: DFE), a leading manufacturer of high performance, cost-effective solar electric modules, today announced that the China Patent & Trademark office has issued a decision to award the company a patent for its core Day4 Electrode solar technology. The Chinese patent approval adds to existing intellectual property protection the company holds in key global markets including the European Union, United States, India and Mexico.

MedMira Awarded China Patent to Complete IP Triple Crown

Rapid Flow-Through Technology Patents in Three Major Global Markets HALIFAX (CNW) - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostics, announced today that it received a Notice on Grant of Patent Right For Invention (equivalent to the Notice of Allowance in the United States) from the State Intellectual Property Office (SIPO) of the People's Republic of China for its rapid diagnostic device and assay (Chinese Patent Application No. 02819646.5). The novel invention is the rapid flow-through technology (RFT) platform, the core product engine upon which the company has built its successful line of rapid tests for diseases such as HIV and Hepatitis. This patent rounds out MedMira's IP "triple crown" along with similar patents awarded in the United States (Patent Application No.

MedMira Awarded China Patent

MedMira Inc. announced that it received a Notice on Grant of Patent Right For Invention (equivalent to the Notice of Allowance in the United States) from the State Intellectual Property Office (SIPO) of the People's Republic of China for its rapid diagnostic device and assay (Chinese Patent Application No. 02819646.5). The novel invention is the rapid flow-through technology (RFT) platform, the core product engine upon which the company has built its successful line of rapid tests for diseases such as HIV and Hepatitis. This patent rounds out MedMira's IP "triple crown" along with similar patents awarded in the United States (Patent Application No. 10/163,675) and the European Union (European Patent No. EP1417489).

Surfware, Inc. Announces U.S. Patent Office Notice of Allowance for Engagement Milling...

Surfware, Inc. Announces U.S. Patent Office Notice of Allowance for Engagement Milling (TrueMill) CAMARILLO, Calif., Aug. 19 /PRNewswire/ -- Surfware, Inc., developer of innovative CAD/CAM software for machining, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its Engagement Milling technology. A Notice of Allowance signifies that the application has been examined and is allowed for issuance as a patent. The U.S. Patent Office accepted all key aspects of the company's patent application. "We are pleased to receive this Notice of Allowance because it serves to protect the intellectual property and proprietary technology that we have developed," says Stephen Diehl, President and CEO of Surfware.

Supreme Court strengthens patent exhaustion doctrine

The United States Supreme Court has unanimously held in Quanta Computer, Inc. v. LG Electronics, Inc. that the patent law cannot be used to control the subsequent use or disposition of a product "that substantially embodies a patent" once the product has been sold with authority of the patent owner. "The authorized sale of an article that substantially embodies a patent exhausts the patent holder's rights and prevents the patent holder from invoking the patent law to control post-sale use of the article." Patent exhaustion applies whether the patents are directed to products or methods. "Our precedents do not differentiate transactions involving embodiments of patented methods or processes from those involving patented apparatuses or materials.

Drugs industry protecting 'morally unacceptable' patent system

Add our medical news to digg - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to NewsVine - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Fark - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Furl - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Shadows - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to YahooMyWeb - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Reddit -Drugs industry protecting 'morally unacceptable' patent system Add our medical news to StumbleUpon - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Facebook - Drugs industry protecting 'morally unaccep

Alnylam Provides Update on "Glover" Patent

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the Glover patent (EP 1230375), which is exclusively licensed to Alnylam from Cancer Research Technology Limited (CRT), has completed initial oral opposition proceedings in Europe. Through these proceedings, the Opposition Division of the European Patent Office has overturned the previously granted claims of the patent which covered certain features of RNAi therapeutics. Alnylam intends to appeal any decision which does not result in the patent being maintained in its present form or scope. The Glover patent is one of many issued or granted so-called "fundamental" patents in Alnylam's broad intellectual property (IP) estate for RNAi therapeutics.

Alnylam Provides Update on "Glover" Patent

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the Glover patent (EP 1230375), which is exclusively licensed to Alnylam from Cancer Research Technology Limited (CRT), has completed initial oral opposition proceedings in Europe. Through these proceedings, the Opposition Division of the European Patent Office has overturned the previously granted claims of the patent which covered certain features of RNAi therapeutics. Alnylam intends to appeal any decision which does not result in the patent being maintained in its present form or scope. The Glover patent is one of many issued or granted so-called "fundamental" patents in Alnylam's broad intellectual property (IP) estate for RNAi therapeutics.

Alnylam Provides Update on "Glover" Patent

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 10, 2008 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the Glover patent (EP 1230375), which is exclusively licensed to Alnylam from Cancer Research Technology Limited (CRT), has completed initial oral opposition proceedings in Europe. Through these proceedings, the Opposition Division of the European Patent Office has overturned the previously granted claims of the patent which covered certain features of RNAi therapeutics. Alnylam intends to appeal any decision which does not result in the patent being maintained in its present form or scope. The Glover patent is one of many issued or granted so-called "fundamental" patents in Alnylam's broad intellectual property (IP) estate for RNAi therapeutics.

Silence Therapeutics Announces Successful Opposition of Glover Patent

a leading European RNA interference (RNAi) focused biotechnology company, announced today the successful opposition of a fundamental Alnylam Pharmaceuticals, Inc. European patent resulting in the patent being revoked in its entirety. The Opposition Division of the European Patent Office, following a three day hearing, announced its decision to revoke European Patent EP 1 230 375, exclusively licensed to Alnylam Pharmaceuticals from Cancer Research Technology, Ltd (UK). The Patent, commonly referred to as the "Glover" patent, broadly relates to medicaments comprising an RNA interference mediating RNA molecule. Opposition briefs to the Glover patent had been filed by Silence Therapeutics AG, Sanofi-Aventis Deutschland GmbH, Quark Biotech, Inc.

Surfware, Inc. Announces U.S. Patent Office Notice of Allowance for Engagement Milling (TrueMill)

CAMARILLO, Calif., Aug. 19 /PRNewswire/ -- Surfware, Inc., developer of innovative CAD/CAM software for machining, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its Engagement Milling technology. A Notice of Allowance signifies that the application has been examined and is allowed for issuance as a patent. The U.S. Patent Office accepted all key aspects of the company's patent application. "We are pleased to receive this Notice of Allowance because it serves to protect the intellectual property and proprietary technology that we have developed," says Stephen Diehl, President and CEO of Surfware. "The mathematics and science behind Engagement Milling are revolutionary, and we have incorporated that technology into our SURFCAM product line as TrueMill(R).

Gene Bridges granted Patents in Japan and Mexico for Recombineering Technology

Gene Bridges GmbH announced that it has been granted patents in Japan and in Mexico relating to the Company's recombineering technology. The Japanese Patent (No. 4139561) was entitled "Novel DNA Cloning Method" while the Mexican Patent (No. 252928) was entitled "Methods and compositions for directed cloning and subcloning using homologous recombination". Both patents broadly cover the major areas of Gene Bridges' RED/ET Recombination technology. This is the same technology that is already covered by issued patents in the USA, EU, Korea and Israel.

Search took 0.60 seconds.